Irreversible Electroporation Ablation for Colorectal Metastases to the Lung
| Status: | Completed |
|---|---|
| Conditions: | Lung Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 1/10/2018 |
| Start Date: | May 2015 |
| End Date: | February 2017 |
The investigators are investigating the use of a new cancer treatment called Irreversible
Electroporation (IRE). This treatment delivers electrical energy between two needles placed
in a cancer. The electrical energy causes cells to die. While this has been used in patients
for different applications, the investigators are trying to understand how safe and well it
works in colon cancer that has spread to the lung. Once the irreversible electroporation
procedure is completed during the operation, the surgeon will then remove the cancer
according to standard procedure. As part of the study, they will be measuring safety of the
electrical energy delivered and will be reviewing the resected specimen under the microscope.
Electroporation (IRE). This treatment delivers electrical energy between two needles placed
in a cancer. The electrical energy causes cells to die. While this has been used in patients
for different applications, the investigators are trying to understand how safe and well it
works in colon cancer that has spread to the lung. Once the irreversible electroporation
procedure is completed during the operation, the surgeon will then remove the cancer
according to standard procedure. As part of the study, they will be measuring safety of the
electrical energy delivered and will be reviewing the resected specimen under the microscope.
Inclusion Criteria:
- Diagnosed Colorectal cancer with oligometastatic colorectal cancer in the lung
- Lung lesion size is greater than 1 cm
- Patient will undergo surgical resection as per consultation with their thoracic
surgeon and medical oncologist
- Patient is cleared to undergo paralytic anesthesia.
- Patients 18 years old and older
Exclusion Criteria:
- Patients with history of cardiac dysrhythmia
- Known heart failure (EF < 40%)
- Pacemaker/defibrillator
- Patient's with any metallic cardiac implant
- Patient on anti-coagulation therapy and are unable to stop therapy for the
perioperative period
- Women who are pregnant and/or nursing
We found this trial at
4
sites
1275 York Ave
New York, New York 10021
New York, New York 10021
(212) 639-2000
Phone: 212-639-5012
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials